Patents by Inventor Juan Carlos Tercero

Juan Carlos Tercero has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20240000816
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Application
    Filed: April 11, 2023
    Publication date: January 4, 2024
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Robert E. COLEMAN, Roger GOMIS
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20230381209
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Application
    Filed: February 15, 2023
    Publication date: November 30, 2023
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Roger GOMIS, Robert E. COLEMAN
  • Therapeutic treatment of breast cancer based on c-MAF status
    Patent number: 11654153
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: May 23, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Robert E. Coleman, Roger Gomis
  • Therapeutic treatment of breast cancer based on c-MAF status
    Patent number: 11596642
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: March 7, 2023
    Assignee: INBIOMOTION S.L.
    Inventors: Walter Martin Gregory, Juan Carlos Tercero, Roger Gomis, Robert E. Coleman
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20210137952
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 13, 2021
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Robert E. COLEMAN, Roger GOMIS
  • Binding members for human c-MAF
    Patent number: 10793642
    Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: October 6, 2020
    Assignee: INBIOMOTION S.L.
    Inventors: Roger Gomis, Juan Carlos Tercero
  • THERAPEUTIC TREATMENT OF BREAST CANCER BASED ON C-MAF STATUS
    Publication number: 20190269707
    Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.
    Type: Application
    Filed: May 25, 2017
    Publication date: September 5, 2019
    Applicant: INBIOMOTION S.L.
    Inventors: Walter Martin GREGORY, Juan Carlos TERCERO, Roger GOMIS, Robert E. COLEMAN
  • BINDING MEMBERS FOR HUMAN C-MAF
    Publication number: 20170369589
    Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 28, 2017
    Applicant: INBIOMOTION S.L.
    Inventors: Roger GOMIS, Juan Carlos TERCERO
  • Prognostic Molecular Markers for ET-743 Treatment
    Publication number: 20100267732
    Abstract: The present invention relates to the use of ecteinascidin 743 in human patients having certain molecular markers profile which has been associated with the outcome of ET-743 chemotherapy. In particular, the invention relates to the use of ecteinascidin 743 in patients having high expression levels of XPG mRNA or protein and/or having a “wild type” genotype for Asp1104His SNP of XPG gene.
    Type: Application
    Filed: October 20, 2008
    Publication date: October 21, 2010
    Applicant: PHARMA MAR, S.A.
    Inventors: Rafael Rosell Costa, Miguel Tarón Roca, Nerea Martínez Magunacelaya, Ana Díez Rodríguez, José Mª Jimeno Donaque, Juan Carlos Tercero López
  • Prognostic Molecular Markers
    Publication number: 20080293725
    Abstract: The present invention relates to the use of ecteinascidin 743 in patients having certain levels of molecular markers who can predict the outcome of chemotherapy, in particular in patients having low levels of BRCA1 expression.
    Type: Application
    Filed: July 11, 2005
    Publication date: November 27, 2008
    Inventors: Rafael Rosell Costa, Miguel Taron Roca, Jose Maria Jimeno Donaque, Juan Carlos Tercero Lopez
  • Immobilisation of ligands
    Publication number: 20040115685
    Abstract: Oligonucleotide is immobilised to a surface using a saccharide or related polymer with at least two different functionalities.
    Type: Application
    Filed: February 3, 2004
    Publication date: June 17, 2004
    Inventors: Juan Carlos Tercero, Lucia Garcia, Jose Manuel Guisan, Roberto Fernandez, Manuel Fuentes